Narrative Review
Idiopathic Retroperitoneal Fibrosis: A Review of the Pathogenesis and Approaches to Treatment

https://doi.org/10.1053/j.ajkd.2009.04.019Get rights and content

Idiopathic retroperitoneal fibrosis (IRPF) is an increasingly recognized syndrome. The development of inflammation and fibrosis in the retroperitoneum most often results in a periaortic mass on computed tomography or magnetic resonance imaging that causes pain and constitutional symptoms. Its organ involvement results in urinary tract obstruction, bowel dysfunction, and venous compression with leg swelling, or thrombosis. The syndrome appears autoimmune in nature, but has no specific immunologic markers. However, nonspecific inflammatory indicators, such as sedimentation rate and C-reactive protein level, reflect disease activity and therapeutic response. Retroperitoneal fibrosis also can arise secondary to inflammatory, infectious, or malignant disease in retroperitoneal organs, in which case treatment is directed at the primary process. However, in patients with IRPF, initial treatment of the local mechanical complications must be followed by medical therapy with corticosteroids or, more recently, the addition of steroid-sparing agents.

Although there are no controlled therapeutic trials, a number of reports with as few as 3 or as many as 28 cases describe sustained and effective steroid-sparing treatment with cyclophosphamide, azathioprine or colchicine, or such newer agents as mycophenolate mofetil or tamoxifen. Overall, IRPF responds to corticosteroid therapy initially but recurs without prolonged treatment. Sustained remission can be attained with steroid-sparing treatment. Kidney function can be preserved, and local organ dysfunction can remit for periods of 10 years or more. Although not randomized or controlled, the evidence convincingly supports a combination of initial surgical or urological intervention, along with early corticosteroid therapy for up to 6 months followed by either mycophenolate or tamoxifen for 1 to 3 years. What was previously believed to be an uncommon and challenging syndrome can be treated successfully when recognized by its characteristic presentation.

Section snippets

Pathogenesis of Idiopathic Disease

Review of the literature9, 11, 29, 44 suggests that in patients with retroperitoneal fibrosis, less than 25% will have an identifiable primary disease process, such as aortic aneurysm, malignancy, previous urinary infection, obstruction, immunologic, or inflammatory syndrome, or use of a known offending pharmacological agent. In the remainder of cases, the cause is unknown, consigning these cases to the idiopathic category, or IRPF.

Histological examination of IRPF specimens generally shows

General Approach to Treatment

The initial approach to IRPF often requires surgical, urological, or medical intervention to address anatomic complications. This may supersede the initiation of medical therapy directed at the underlying inflammatory and fibrotic process. For example, ureteral obstruction usually responds to stent placement, but sometimes requires ureterolysis5, 6, 8, 9, 10, 29, 57, 58 or even occasional nephrectomy; bowel obstruction requires evaluation, observation, and even diversion before

Recommendations and Conclusions

Previous teaching has characterized IRPF as rare, often difficult to diagnose, complicated to treat, and boding a guarded prognosis. However, review of the growing body of evidence, albeit uncontrolled, strongly suggests several important principles concerning IRPF: (1) the condition may be more common than we thought; (2) disease activity appears to be an idiopathic inflammatory and fibrotic response of autoimmune type with as yet unidentified inciting pathogenesis, and although some

Acknowledgements

Support: None.

Financial Disclosure: None.

References (73)

  • D. Corradi et al.

    Idiopathic retroperitoneal fibrosis: Clinicopathologic features and differential diagnosis

    Kidney Int

    (2007)
  • M. Stifelman et al.

    Minimally invasive management of retroperitoneal fibrosis

    Urol

    (2008)
  • A. Srinivasan et al.

    Comparison of laparoscopic with open approach to ureterolysis in patients with retroperitoneal fibrosis

    J Urol

    (2008)
  • A. Kardar et al.

    Steroid therapy for idiopathic retroperitoneal fibrosis: Dose and duration

    J Urol

    (2002)
  • P. Scheel et al.

    Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis

    J Urol

    (2007)
  • T. Moody et al.

    Steroids in the treatment of retroperitoneal fibrosis

    J Urol

    (1979)
  • G. Buckberg et al.

    The protean manifestations of sclerosing fibrosis

    Surg Gynecol Obstet

    (1966)
  • L. Baker et al.

    Idiopathic retroperitoneal fibrosis: A restrospective analysis of 60 cases

    Br J Urol

    (1989)
  • C. Ilie et al.

    Idiopathic retroperitoneal fibrosis: The case for non-surgical treatment

    Br J Urol

    (2006)
  • E. Von Bommel et al.

    Brief communication: Tamoxifen therapy for nonmalignant retroperitoneal fibrosis

    Ann Intern Med

    (2006)
  • R. Swartz et al.

    Idiopathic retroperitoneal fibrosis: A role for mycophenolate mofetil

    Clin Nephrol

    (2008)
  • A. Fry et al.

    Successful use of steroids and ureteric stents in 24 patients with idiopathic retroperitoneal fibrosis: A retrospective study

    Nephron Clin Pract

    (2008)
  • I. Vivas et al.

    Retroperitoneal fibrosis: Typical and atypical manifestations

    Br J Radiol

    (2000)
  • N. Twahirwa et al.

    Unusual presentation of idiopathic retroperitoneal fibrosis: Case report

    E Afr Med J

    (2008)
  • C. Bahler et al.

    Mediastinal fibrosis in a patient with idiopathic retroperitoneal fibrosis

    Interact Cardiovasc Thorac Surg

    (2008)
  • A. Klisnick et al.

    Combined idiopathic retroperitoneal and mediastinal fibrosis with pericardial involvement

    Clin Nephrol

    (1999)
  • E. Amiya et al.

    Retroperitoneal fibrosis with periaortic and pericardial involvement

    Circ J

    (2005)
  • P. Reittner et al.

    Orbital pseudotumor due to Ormond's disease: MR imaging and CT findings

    Neuroradiology

    (2002)
  • K. Tang et al.

    Primary biliary cirrhosis and idiopathic retroperitoneal fibrosis: A rare association

    Eur J Gastroenterol Hepatol

    (2002)
  • O. Kaipiainen-Seppanen et al.

    Retroperitoneal fibrosis with antineutrophil cytoplasmic antibody

    J Rheumatol

    (1996)
  • P. Martinez-Odriozola et al.

    Association of idiopathic retroperitoneal fibrosis, rapidly progressive glomerulonephritis and antiproteinase 3 antineutrophil cytoplasmic antibody

    Clin Nephrol

    (2008)
  • M. Yamamoto et al.

    The significance of disease-independence in Mikulicz's disease

    Nihon Rinsh Men Gak Kaishi

    (2006)
  • P. Colin et al.

    Retroperitoneal infiltration as the first sign of Erdheim-Chester disease

    Int J Urol

    (2008)
  • H. Hellstrom et al.

    Retroperitoneal fibrosis with disseminated vasculitis and intraphepatic sclerosing cholangitis

    Am J Med

    (1965)
  • E. Littman

    Renal amyloidosis with nephritic syndrome associated with retroperitoneal fibrosis

    Ann Intern Med

    (1971)
  • G. Waaler

    Idiopathic retroperitoneal fibrosis

    Scand J Urol Nephrol

    (1975)
  • Cited by (0)

    Originally published online as doi: 10.1053/j.ajkd.2009.04.019 on June 11, 2009.

    View full text